News & Media

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

October 14, 2021, Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC: HMTXF; FRA:2VFO) is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer.  

Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis Health at Doctors Hospital, staff at University of Maryland Capitol Region Medical Center and Director of the Chiari Syringomyelia Foundation Greater Metropolitan Washington Chapter, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in genetic disorders of the craniocervical junction. He was recipient of the American Association of Neurological Surgeons/CNS Award for Excellence in Spine Research in 2007, and the RISES Physicians award at The Adventist Shady Grove Hospital in 2011. The inventor of 13 patents relating to disorders of the brainstem and spinal cord, Dr. Henderson has published over 100 peer reviewed articles and book chapters, and given over 190 invited lectures with a focus on craniocervical disorders, genetic disorders, cancer, radiosurgery and unusual problems of the spine.

Fraser Henderson was foreman on a cattle station in the Outback of Australia before receiving his Bachelor’s and Medical degrees at the University of Virginia, Charlottesville VA.  Dr. Henderson served for with the Multi-National Peace Keeping Force in Beirut, earning the Navy Commendation Medal for treatment of mass casualties following the terrorist bombing attack in Beirut, Lebanon, October1983. After completing his residency under Phanor Perot at the Medical University of South Carolina, he returned to complete his active duty obligation at the National Naval Medical Center, Bethesda, MD, as Director of Spine. He was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. He then completed a fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London.

Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Craniocervical Junction and Spine.  He was also Co-Director of the Lombardi Neuro-Oncology Division and Co- Director of the CyberKnife Radiosurgery Center, where he was active in advancing stereotactic radiosurgery for treatment of complex spinal tumors. He was Principal Investigator in the translational development of a radio-sensitizing drug and a drug to block the malignant invasiveness of Glioblastoma Multiform. In 2005, Dr Henderson was promoted to Professor of Neurosurgery. He serves on the Executive Boards of the Bobby Jones Chiari Syringomyelia Foundation, the Ehlers Danlos Society, The ILC and TCAPP foundations.

 “For decades an autologous cell-based therapy for brain and spinal cord injuries has been the Holy Grail for neurological surgeons and their patients. It is my privilege to join the team that is shepherding this promise to clinical fruition”, said Dr. Henderson.

“Dr. Henderson’s 12 grant funded research studies, his neurosurgical expertise and extensive experience overlaps many of the properties of Hemostemix stem cells, including NCP’s nerve growth factors and responses, NCP’s secretions of neurotrophin and neuroepithelial stem cell protein, and the generation of vascular endothelial growth factors,” stated Thomas Smeenk, CEO. “Our team look forward to unlocking the value of NCP and BCP, in parallel to ACP, with Dr. Henderson’s guidance.  As well, our board of directors and management team would like to thank Dr. Pierre Leimgruber whole heartedly for his excellent counsel, direction, dedication, and collegiality,” stated Smeenk.


Hemostemix is in compliance with new amendments adopted by the US Securities and Exchange Commission in relation to OTC Markets. Hemostemix confirms that its financial disclosure and company information is up to date and filed on SEDAR. Hemostemix has filed its application to up-list the Company’s shares to the OTCQB.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01Trial with 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit

For further information, please contact:

Contact: Thomas Smeenk, President, CEO & Co-Founder 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the completion of the follow-up for Hemostemix’s ACP-01 clinical trial and the source document verification process; the status of Hemostemix’s Litigation (as defined below); and the commercialization of ACP-01. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the “Litigation”); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies as well as management’s ‎expectations of anticipated results; Hemostemix’s general and administrative costs remaining constant; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix’s services and products; competition and ‎Hemostemix’s competitive advantages; and Hemostemix obtaining satisfactory financing to ‎fund Hemostemix’s operations including any research, trials or studies, and the Litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory analyses and the results of such analyses and future clinical ‎trials; ‎litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, ‎service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and  ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix ‎offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View All News & Media